American Society of Hirudotherapy

Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban

Nested case-control study published in Journal of thrombosis and haemostasis : JTH (2021)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Randomized controlled trialClinical LiteratureBosch FTM et al. · Journal of thrombosis and haemostasis : JTH, 2021

Abstract

BACKGROUND: In the Hokusai VTE Cancer study, the risk of major bleeding was 2.9% higher in the edoxaban group compared with the dalteparin group, mainly due to more gastrointestinal bleedings in patients with gastrointestinal cancer. The identification of risk factors for gastrointestinal bleeding may help to guide the use of DOACs in these patients. OBJECTIVES: To evaluate risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer receiving edoxaban. PATIENTS/METHODS: In this nested case-control study in patients with gastrointestinal cancer randomized to edoxaban in the Hokusai VTE Cancer study, cases (patients with clinically relevant gastrointestinal bleeding during treatment) were randomly matched to three controls (patients who had no gastrointestinal bleeding). Data for the 4-week period prior to bleeding were retrospectively collected. Odds ratios (ORs) were calculated in a crude conditional logistic regression model and a multivariable model adjusted for age, sex, and cancer type. RESULTS: Twenty-four cases and 64 matched controls were included. In the multivariable analysis, advanced cancer, defined as regionally advanced or metastatic cancer (OR 3.6, 95% CI 1.01-12.6) and low hemoglobin levels (OR 4.8, 95% CI 1.5-16.0) were significantly associated with bleeding. There was no significant difference in patients with resected tumors (OR 0.4, 95% CI 0.1-1.4), or in patients on chemotherapy (OR 1.3, 95% CI 0.5-3.5). CONCLUSION: Advanced cancer and low hemoglobin levels were associated with an increased risk of gastrointestinal bleeding in patients with gastrointestinal cancer receiving edoxaban. We were unable to identify other risk factors, mainly due to limited statistical power.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleRandomized Controlled TrialResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnticoagulantsCase-Control StudiesFactor Xa InhibitorsGastrointestinal HemorrhageGastrointestinal NeoplasmsHumansPyridinesRetrospective StudiesRisk FactorsThiazolesVenous Thromboembolism

Summary

In a nested case-control analysis of Hokusai VTE Cancer patients with gastrointestinal cancer on edoxaban, advanced (regionally advanced or metastatic) cancer (OR 3.6) and low hemoglobin (OR 4.8) were associated with clinically relevant gastrointestinal bleeding.

Why This Matters for Hirudotherapy

This nested case-control analysis within the Hokusai VTE Cancer randomized trial evaluated why edoxaban-treated patients with gastrointestinal cancer bled more, and found that advanced (regionally advanced or metastatic) cancer and low hemoglobin were significantly associated with gastrointestinal bleeding, while resected tumors and chemotherapy were not. Its relevance to hirudotherapy is as bleeding-risk context: it illustrates how patient factors amplify hemorrhage risk on a potent anticoagulant, a directly analogous concern when applying leeches, whose saliva produces sustained local anticoagulation, to patients who are already anticoagulated or have advanced malignancy and anemia. The caveat is that the analysis is observational (nested case-control) and explicitly underpowered, with wide confidence intervals and only 24 bleeding cases, so its associations are exploratory and it concerns the oral anticoagulant edoxaban, not leech therapy.

Citation

Reference (Vancouver style)

Bosch FTM, Mulder FI, Huisman MV, Zwicker JI, Di Nisio M, Carrier M, et al. Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. J Thromb Haemost. 2021;19(12):3008-3017. doi:10.1111/jth.15516. PMID: 34455706

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.